Avery Dennison Announces 510(k) Clearance of New Chlorhexidine Gluconate (CHG) Transparent Film Dressing

CHICAGO--(BUSINESS WIRE)--Avery Dennison Medical Solutions, a business unit of Avery Dennison Corporation (NYSE: AVY), announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Chlorhexidine Gluconate (CHG) transparent film dressing, known as BeneHold™ CHG Transparent Film Dressing. In-vitro test data demonstrate the new dressing’s antimicrobial efficacy across a broad range of bacteria and yeast commonly found in catheter-related blood stream infections.